Human Stem Cell Nociceptor Differentiation Without Murine Stromal Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating embryonic and somatic stem cells into peripheral sensory neurons, particularly nociceptors, are limited by the need for murine stromal cells, low yield, impure cell populations, and prolonged timeframes, with challenges in obtaining human peripheral sensory neurons from manual isolation or surgical procedures.
Innovation Solution
A method involving culture conditions that inhibit SMAD, FGF, and Notch signaling while activating Wnt signaling, using inhibitors like SB431542, LDN193189, SU5402, CHIR99021, and DAPT, allows direct differentiation of human pluripotent stem cells into nociceptors without murine stromal cells, achieving high purity and yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If manual isolation or surgical procedures are used to obtain human peripheral sensory neurons, then cell acquisition is possible, but the yield is low and the process is time-consuming
Solution Approach 1:
The invention changes the differentiation parameters by using a specific sequence of signaling pathway modulators (BMP inhibition followed by FGF and Notch inhibition) to direct stem cell differentiation toward nociceptor lineage, achieving high-yield production of functional nociceptors in vitro within days, eliminating the need for manual isolation or surgical procedures
Solution Approach 2:
The stem cells are induced to self-differentiate into nociceptors through controlled signaling pathway modulation, eliminating the need for external cell isolation techniques. The cells autonomously undergo the differentiation process when exposed to the defined culture conditions and signaling inhibitors
2Manufacturing precision
If traditional differentiation methods are used, then nociceptors can be produced, but the cell population purity is low and requires murine stromal cells
Solution Approach 1:
The invention extracts and eliminates the requirement for murine stromal cells from the differentiation system by using a defined culture medium with specific signaling pathway modulators, achieving high-purity human nociceptor production without contaminating cell types or complex co-culture requirements
Solution Approach 2:
The invention changes the cultural parameters from undefined serum-containing media with stromal cells to defined differentiation media with specific signaling inhibitors (BMP, FGF, Notch), achieving both high purity and simplified system complexity
3Adaptability or versatility
If conventional stem cell differentiation protocols are used, then general neuronal differentiation is achieved, but specific nociceptor differentiation is not obtained
Solution Approach 1:
The invention segments the differentiation process into distinct phases targeting specific signaling pathways: initial BMP inhibition for neural commitment, followed by FGF and Notch inhibition for nociceptor specification, enabling precise control over differentiation fate toward nociceptors rather than general neurons
Solution Approach 2:
The invention uses small molecule signaling pathway modulators as intermediaries to translate external differentiation cues into specific cellular responses, with BMP, FGF, and Notch inhibitors serving as mediators to direct stem cells through defined differentiation stages toward nociceptor lineage
Data Source
AI summary
The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.